The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
One important use of American kestrels is in falconry. It is often considered a beginner's bird, though the careful weight control needed to maintain the kestrel's desire to aggressively hunt takes skill. Falconers experienced in extracting the best performance the species is capable of, report they are highly reliable on the normal game of sparrows and starlings. More aggressive individuals are sometimes capable of capturing prey up to approximately twice their own body weight, allowing the occasional capture of true game birds such as quail and dove. However, most falconers interested in the reliable taking of such game do prefer larger falcons or hawks. The advantage the American kestrel offers the experienced falconer is its suitability to simple and urban falconry not requiring large tracts of land or the use of hunting dogs. This form of falconry is sometimes referred to as "micro-falconry" or "micro-hawking". The other small raptor species commonly used in micro-falconry are the merlin, the sharp-shinned hawk (the smallest Accipiter), and the European kestrel (a true kestrel). Hawking with the American kestrel requires adapting to the strengths and weaknesses of the bird. It is a tiny falcon, and even for its size, it is less muscular than other small falcons such as the athletic and swift merlin. It is more adapted to ambush hunting and short chases than to the longer aerial chases larger falcons often adopt. Used within its limits, it is effective.
During its fourth year, Gearbox began working on its first independently owned game: Brothers in Arms: Road to Hill 30. Developed for PC and Microsoft's Xbox console, and built with the Unreal Engine 2, it was released in March 2005. The sequel, Brothers in Arms: Earned in Blood, followed seven months later. The series was published by Ubisoft, who supported both games with PlayStation 2 versions, and later worked with it to develop Brothers in Arms games for portable systems (mobile phones, PlayStation Portable and Nintendo DS) and the Wii home console. In 2005, Gearbox licensed the Unreal Engine 3 from Epic Games, to replace the Unreal Engine 2 technology used in previous games, and grew its internal development teams to handle the demands of next-generation technology and content. Brothers in Arms: Hell's Highway was the first new title to be announced, continuing the company's flagship franchise. Brothers in Arms: Hell's Highway was launched in September 2008. By 2008, the franchise also spun off a comic book series, a two-part television documentary, a line of action figures, and a novelization and non-fiction history book.
=== Electrogenetics === Mammalian designer cells are engineered by humans to behave a specific way, such as an immune cell that expresses a synthetic receptor designed to combat a specific disease. Electrogenetics is an application of synthetic biology that involves utilizing electrical fields to stimulate a response in engineered cells. Controlling the designer cells can be done with relative ease through the use of common electronic devices, such as smartphones. Additionally, electrogenetics allows for the possibility of creating devices that are much smaller and compact than devices that use other stimulus through the use of microscopic electrodes. One example of how electrogenetics is used to benefit public health is through stimulating designer cells that are able to produce/deliver therapeutics. This was implemented in ElectroHEK cells, cells that contain voltage-gated calcium channels that are electrosensitive, meaning that the ion channel can be controlled by electrical conduction between electrodes and the ElectroHEK cells. The expression levels of the artificial gene that these ElectroHEK cells contained was shown to be able to be controlled by changing the voltage or electrical pulse length. Further studies have expanded on this robust system, one of which is a beta cell line system designed to control the release of insulin based on electric signals.
Mick Anglo (born Maurice Anglowitz, 19 June 1916 – 31 October 2011) of Russian Jewish ancestry, was a British comic book writer, editor and artist, as well as an author. He is best known for creating the superhero Marvelman, later known as Miracleman, a character later revived in 1982 in a dark, post-modern reboot by writer Alan Moore, with later contributions by Neil Gaiman. Lisa Appignanesi (born 4 January 1946) writer, novelist, campaigner for free expression; was Chair of the Royal Society of Literature; former President of English PEN; Chair of Freud Museum; chaired 2017 Booker International Prize; Honorary Fellow of St Benet's Hall, Oxford and visiting professor in the Department of English at King's College London, and held a Wellcome Trust; has written for The New York Review of Books, The Guardian and The Observer, as well as making programmes and appearing on the BBC; was Director of Talks and Seminars at the Institute of Contemporary Arts (ICA) in London; was made a Chevalier of the Ordre des Arts et des Lettres and was appointed Officer of the Most Excellent Order of the British Empire (OBE) in the 2013 New Year Honours for services to literature. She became a Fellow of the Royal Society of Literature in 2015 and became the Chair of the Royal Society of Literature Council in 2016. Neal Ascherson (born 5 October 1932) journalist and writer; described by Radio Prague as "one of Britain's leading experts on central and eastern Europe".
Sources: en.wikipedia.org
In 1993, the FDA issued a document for the content limits of DON in food and animal feed at an advisory level. In 2003, US published a patent that is very promising for farmers to produce a trichothecene-resistant crop. Zearalenone Zearalenols
Atmosphere of the Sun: in detectable trace amounts Atmosphere of Mercury: 3.4%, and large amounts of water in Mercury's exosphere Atmosphere of Venus: 0.002% Earth's atmosphere: ≈0.40% over full atmosphere, typically 1–4% at surface Atmosphere of the Moon: in trace amounts Atmosphere of Mars: 0.03% Atmosphere of Ceres Atmosphere of Jupiter: 0.0004% – in ices only; and that of its moon Europa Atmosphere of Saturn – in ices only; Enceladus: 91% and Dione (subsurface ocean) Atmosphere of Uranus – in trace amounts below 50 bar Atmosphere of Neptune – found in the deeper layers Extrasolar planet atmospheres: including those of HD 189733 b and HD 209458 b, Tau Boötis b, HAT-P-11b, XO-1b, WASP-12b, WASP-17b, and WASP-19b. Stellar atmospheres: not limited to cooler stars and even detected in giant hot stars such as Betelgeuse, Mu Cephei, Antares and Arcturus. Circumstellar disks: including those of more than half of T Tauri stars such as AA Tauri as well as TW Hydrae, IRC +10216 and APM 08279+5255, VY Canis Majoris and S Persei.
== Pathophysiology == In normal metabolism, the elevated blood glucose level causes beta (β) cells in the Islets of Langerhans, located in the pancreas, to release insulin into the blood. The insulin makes insulin-sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose which provides energy as well as lowers blood glucose, in a negative feedback loop. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a homeostatic constant level of approximately 5 mmol/L (90 mg/dL). In an insulin-resistant individual, normal levels of insulin do not have the same effect in controlling blood glucose levels. When the body produces insulin under conditions of insulin resistance, the cells are unable to absorb or use glucose as effectively and it stays in the bloodstream. Certain cell types such as fat and muscle cells require insulin to absorb glucose and when these cells fail to respond adequately to circulating insulin, blood glucose levels rise. Skeletal muscle is thought to be particularly important in this regard. The liver normally helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. However, in insulin resistance, this normal reduction in the liver's glucose production may not occur, further contributing to elevated blood glucose. Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels.
=== Regulation === In vertebrates, the secretion of melatonin is regulated through the activation of the beta-1 adrenergic receptor by the hormone norepinephrine. Norepinephrine increases the concentration of intracellular cAMP via beta-adrenergic receptors, which in turn activates the cAMP-dependent protein kinase A (PKA). PKA then phosphorylates arylalkylamine N-acetyltransferase (AANAT), the penultimate enzyme in the melatonin synthesis pathway. When exposed to daylight, noradrenergic stimulation ceases, so AANAT is not phosphorylated. In the absence of phosphorylation, AANAT is immediately degraded by proteasomal proteolysis. Blue light, especially within the 460–480 nm range, inhibits the biosynthesis of melatonin, with the degree of suppression being directly proportional to the intensity and duration of light exposure. Historically, humans in temperate climates experienced limited exposure to blue daylight during winter months, primarily receiving light from sources that emitted predominantly yellow light, such as fires. The incandescent light bulbs used extensively throughout the 20th century emitted relatively low levels of blue light. It has been found that light containing only wavelengths greater than 530 nm does not suppress melatonin under bright-light conditions. The use of glasses that block blue light in the hours preceding bedtime can mitigate melatonin suppression.
== Overview == The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) who work on very early-stage drug development on very small scale providing medicinal chemistry services. These are now often called CDROs as they provide some small scale development work. CDMOs work on the scale-up and later stages of drug development often preparing materials ranging from hundreds of grams to multi-kilo amounts. As the drug moves through the various clinical stages, the volumes tend to grow as well. Commercial scale amounts could range to metric tons. Over the years, the concept of a comprehensive single-source provider from drug development (a one-stop shop) through commercial manufacture of drug substance and drug product has been tried to varying success. CDMOs are a response to the competitive international nature of the pharmaceutical market as well as the increasing demand for outsourced services. The best-positioned service providers focus on a specific technology or dosage form and promote end-to-end continuity and efficiency for their outsourcing clients. With lower-cost international manufacturers capturing an increasing percentage of the contract manufacturing market, specialization may be an effective hedge against loss of market share.
Sources: en.wikipedia.org
== Concerns == The primary concern of automated synthesis is job displacement. Other concerns are high initial investment and maintenance costs, privacy concerns, and an over-dependence on technology. There are also ethical concerns, regarding the use of artificial intelligence and robotics. See Ethics of artificial intelligence, Robot ethics, Machine ethics. Parts of procedures and techniques were automated throughout the 19th and 20th centuries, using simple circuit boards. The first fully automatic synthesis was a peptide synthesis by Robert Merrifield and John Stewart in 1966. Applications of artificial intelligence to organic synthesis also started in the 1960s with the Dendral Project, which helped organic chemists characterize and identify molecules using mass spectrometry. True computer-assisted organic synthesis software (CAOS) such as LHASA became feasible as artificial intelligence and machine learning developed in the 1980s. Important developments in automated radiosynthetic modules were also made in the 1980s. In the late 1990s, the main challenge of automation was overcoming phase-separation issues and increasing system integration. At this time there were only specific systems that belonged to one of four designs: a flow reactor, a batch reactor connected by flow lines, one robot, two robots: one for synthesis and one for analysis, and special larger systems that were a combination of the aforementioned.
== Veterinary use == Oxymorphone provides up to 5–6 hours of clinical analgesia in dogs and cats following intravenous administration. Intramuscular administration in dogs produces approximately 90 minutes of antinociception. Oxymorphone is ineffective when administered via the oral-transmucosal route in cats, likely due to low bioavailability. Only few reports exist on its use in large animal species due to the cost of oxymorphone.
Dibenzoylmorphine is an opioid analogue that is a derivative of morphine. It was developed in the early 1900s after first having been synthesised in 1875 in the UK by the CR Alders Wright organisation at Bayer, along with various other esters of morphine. It was never used medically, instead being widely sold as one of the first "designer drugs" for around five years following the introduction of the first international restrictions on the sale of heroin in 1925. It is described as being virtually identical to heroin and morphine in its effects, and consequently was itself banned internationally in 1930 by the Health Committee of the League of Nations, in order to prevent its sale as an unscheduled alternative to diacetylmorphine. However, it still continues to occasionally be encountered as a result of home manufacture from morphine by drug users. It is produced in the same fashion as other esters of morphine—treating morphine with an acid anhydride (or some acids or other relatives of acids like acetyl chloride) to get a mono-, di-, tri-, or tetra-ester. Specifically, the original 1875 synthesis was effected by boiling morphine for 2 hours in benzoic anhydride at 130 °C, as was heroin made by using acetic anhydride.
==== Hydration ==== Increasing water intake can reduce weight by increasing thermogenesis, by reducing food intake, and by increasing fat oxidation. Persons dieting for weight loss have demonstrated the weight-reducing effects of increased water consumption. Among adults in the U.S. there is a significant association between inadequate hydration and obesity.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.